Pacira Pharmaceuticals(CH:82P)
CH:82P
Pacira Pharmaceuticals financials statements
Pacira Pharmaceuticals (82P) Ratios
0 Followers
Pacira Pharmaceuticals Ratios
CH:82P's free cash flow for Q3 2026 was $46.45M. For the 2026 fiscal year, CH:82P's free cash flow was decreased by $-3.63M and operating cash flow was $50.07M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.54 | 2.40 | 5.24 | 3.37 | 1.66 |
| Quick Ratio | 3.28 | 2.00 | 4.17 | 2.72 | 1.47 |
| Cash Ratio | 1.31 | 0.89 | 1.57 | 0.70 | 1.12 |
| Solvency Ratio | 0.17 | -0.03 | 0.17 | 0.12 | 0.05 |
| Operating Cash Flow Ratio | 1.26 | 0.61 | 1.59 | 0.98 | 0.24 |
| Short-Term Operating Cash Flow Coverage | 15.45 | 0.94 | 17.90 | 4.32 | 0.34 |
| Net Current Asset Value | $ -23.83M | $ -30.04M | $ -194.26M | $ -407.86M | $ -478.90M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.41 | 0.37 | 0.45 | 0.54 |
| Debt-to-Equity Ratio | 0.66 | 0.82 | 0.67 | 0.99 | 1.55 |
| Debt-to-Capital Ratio | 0.40 | 0.45 | 0.40 | 0.50 | 0.61 |
| Long-Term Debt-to-Capital Ratio | 0.37 | 0.33 | 0.37 | 0.46 | 0.48 |
| Financial Leverage Ratio | 1.82 | 2.00 | 1.81 | 2.17 | 2.84 |
| Debt Service Coverage Ratio | 4.61 | -0.03 | 5.20 | 2.07 | 0.25 |
| Interest Coverage Ratio | 2.28 | -4.43 | 5.06 | 1.69 | 3.10 |
| Debt to Market Cap | 0.36 | 0.67 | 0.33 | 0.39 | 0.39 |
| Interest Debt Per Share | 10.52 | 14.17 | 13.05 | 17.55 | 26.16 |
| Net Debt to EBITDA | 2.41 | 12.43 | 2.80 | 4.70 | 4.77 |
| Profitability Margins | |||||
| Gross Profit Margin | 79.39% | 75.69% | 72.64% | 70.11% | 74.10% |
| EBIT Margin | 4.33% | -7.09% | 11.71% | 7.33% | 15.77% |
| EBITDA Margin | 16.86% | 4.15% | 22.90% | 21.05% | 21.04% |
| Operating Profit Margin | 4.58% | -10.47% | 12.99% | 9.00% | 16.61% |
| Pretax Profit Margin | 2.32% | -9.00% | 9.14% | 1.99% | 10.42% |
| Net Profit Margin | 0.97% | -14.20% | 6.22% | 2.39% | 7.75% |
| Continuous Operations Profit Margin | 0.97% | -14.20% | 6.22% | 2.39% | 7.75% |
| Net Income Per EBT | 41.69% | 157.77% | 68.00% | 119.60% | 74.43% |
| EBT Per EBIT | 50.67% | 86.01% | 70.37% | 22.16% | 62.72% |
| Return on Assets (ROA) | 0.56% | -6.41% | 2.66% | 0.95% | 2.02% |
| Return on Equity (ROE) | 1.01% | -12.79% | 4.82% | 2.05% | 5.75% |
| Return on Capital Employed (ROCE) | 2.91% | -5.90% | 5.94% | 3.91% | 5.79% |
| Return on Invested Capital (ROIC) | 1.20% | -5.05% | 3.99% | 3.81% | 3.46% |
| Return on Tangible Assets | 0.80% | -8.83% | 4.52% | 1.63% | 3.21% |
| Earnings Yield | 0.61% | -11.43% | 2.69% | 0.91% | 1.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.85 | 6.19 | 6.39 | 6.78 | 5.62 |
| Payables Turnover | 9.88 | 8.91 | 11.76 | 13.09 | 13.30 |
| Inventory Turnover | 0.98 | 1.36 | 1.77 | 2.07 | 1.42 |
| Fixed Asset Turnover | 3.98 | 3.24 | 2.87 | 2.62 | 2.04 |
| Asset Turnover | 0.57 | 0.45 | 0.43 | 0.40 | 0.26 |
| Working Capital Turnover Ratio | 1.68 | 1.65 | 1.77 | 1.92 | 1.46 |
| Cash Conversion Cycle | 398.00 | 286.33 | 232.31 | 201.92 | 293.95 |
| Days of Sales Outstanding | 62.34 | 59.00 | 57.08 | 53.86 | 64.92 |
| Days of Inventory Outstanding | 372.59 | 268.31 | 206.25 | 175.94 | 256.47 |
| Days of Payables Outstanding | 36.93 | 40.98 | 31.03 | 27.87 | 27.44 |
| Operating Cycle | 434.93 | 327.31 | 263.33 | 229.79 | 321.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.41 | 4.10 | 3.35 | 3.19 | 2.84 |
| Free Cash Flow Per Share | 3.07 | 3.87 | 3.02 | 2.53 | 1.80 |
| Dividend Paid and CapEx Coverage Ratio | 9.91 | 17.81 | 10.20 | 4.83 | 2.74 |
| Capital Expenditure Coverage Ratio | 9.91 | 17.81 | 10.20 | 4.83 | 2.74 |
| Operating Cash Flow Coverage Ratio | 0.33 | 0.30 | 0.26 | 0.19 | 0.11 |
| Operating Cash Flow to Sales Ratio | 0.21 | 0.27 | 0.23 | 0.22 | 0.23 |
| Free Cash Flow Yield | 11.85% | 20.52% | 8.94% | 6.55% | 3.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 161.75 | -8.76 | 37.17 | 110.48 | 63.44 |
| Price-to-Sales (P/S) Ratio | 1.59 | 1.24 | 2.31 | 2.64 | 4.92 |
| Price-to-Book (P/B) Ratio | 1.66 | 1.12 | 1.79 | 2.27 | 3.65 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 8.44 | 4.87 | 11.18 | 15.26 | 33.35 |
| Price-to-Operating Cash Flow Ratio | 7.59 | 4.60 | 10.08 | 12.10 | 21.18 |
| Price-to-Earnings Growth (PEG) Ratio | -1.51 | 0.03 | 0.23 | -1.75 | -0.88 |
| Enterprise Value Multiple | 11.83 | 42.36 | 12.89 | 17.22 | 28.14 |
| Enterprise Value | 1.45B | 1.23B | 1.99B | 2.42B | 3.21B |
| EV to EBITDA | 11.83 | 42.36 | 12.89 | 17.22 | 28.14 |
| EV to Sales | 2.00 | 1.76 | 2.95 | 3.62 | 5.92 |
| EV to Free Cash Flow | 10.60 | 6.90 | 14.28 | 20.98 | 40.16 |
| EV to Operating Cash Flow | 9.53 | 6.51 | 12.88 | 16.64 | 25.51 |
| Tangible Book Value Per Share | 6.84 | 7.62 | 4.84 | 1.56 | -0.88 |
| Shareholders’ Equity Per Share | 15.55 | 16.83 | 18.83 | 17.03 | 16.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.58 | -0.58 | 0.32 | -0.20 | 0.26 |
| Revenue Per Share | 16.30 | 15.16 | 14.60 | 14.65 | 12.23 |
| Net Income Per Share | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 |
| Tax Burden | 0.42 | 1.58 | 0.68 | 1.20 | 0.74 |
| Interest Burden | 0.54 | 1.27 | 0.78 | 0.27 | 0.66 |
| Research & Development to Revenue | 0.16 | 0.12 | 0.11 | 0.13 | 0.10 |
| SG&A to Revenue | 0.51 | 0.42 | 0.17 | 0.16 | 0.16 |
| Stock-Based Compensation to Revenue | 0.08 | 0.07 | 0.07 | 0.07 | 0.08 |
| Income Quality | 21.61 | -1.90 | 3.69 | 9.13 | 2.99 |
Currency in USD
